Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIIB 059

Drug Profile

BIIB 059

Alternative Names: BIIB-059

Latest Information Update: 14 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Monoclonal antibodies
  • Mechanism of Action C-type lectin antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus

Most Recent Events

  • 06 Feb 2020 Immunogenicity data from a phase I trial for Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARPH -2019)
  • 30 Jan 2020 Biogen plans a phase III trial for Cutaneous lupus erythematosus and systemic lupus erythematosus
  • 03 Dec 2019 Biogen completes the phase II LILAC trial for Cutaneous lupus erythematosus and Systemic lupus erythematosus in USA, Argentina, Bulgaria, Colombia, Israel, Mexico, South Korea, Serbia, Philippines, Poland, Taiwan and Thailand (SC) (NCT02847598)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top